Safety and Efficacy of Acupressure Applied Through ForgTin© in Patients With Tinnitus
NCT ID: NCT04623957
Last Updated: 2020-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
35 participants
INTERVENTIONAL
2020-11-30
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
Group 1 receives the intervention for a duration of three months. This Phase I is followed by a Washout period of one month and by a non-interventional phase (Phase II).
Group 2 receives no initial treatment for a duration of three months (Phase I). This Phase I is followed by a Washout period of one month and by an interventional phase (Phase II). Phase III is introduced for both groups for ethical and motivational purposes and to observe potential long-term effects within Group 2.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ForgTin
Patients randomized into group 1 will receive the ForgTin Medical Device for a duration of 3 months.
ForgTin©
The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.
The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises.
No intervention
Patients randomized into group 2 will receive no device for a duration of 3 months.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ForgTin©
The device is clamped behind the ear via two connected temple parts that pressed together around the connecting axis until an individual perfect wearing comfort is achieved. The pressure is adjusted so that the wearing of ForgTin© is barely noticed at all and may be changed at any time.
The aim is a slight pressure stimulation of clearly defined points behind the ear - thus wearing ForgTin© leads to a minimization of individual tinnitus noises.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjective tinnitus in one or both ears with intermittent or continuous symptoms with a duration of \> 6 months
* Tinnitus of Grade II, III or IV according to Mini-Tinnitus-Questionnaire (Mini-TF12):
* Grade II (score of 8-12): moderately distressed
* Grade III (score of 13-18): severely distressed
* Grade III (score of 19-24): most severely distressed
* If a drug therapy with psychoactive substances (e.g. antidepressants, anticonvulsants) exists at the beginning of the therapeutic intervention, it must have been stable for at least 30 days. The therapy should remain constant during the duration of the study, but a necessary change is not an exclusion criterion. Any change in medication is documented in the CRF.
* Provides written informed consent
Exclusion Criteria
* Objective tinnitus
* Any other tinnitus-related treatment
* Ménière's Disease
* Acute infections of the hearing system (acute otitis media, otitis externa, acute sinusitis)
* Acute infections (acute otitis media, otitis externa, acute sinusitis)
* Hearing aids or Cochlear Implants (CI)
* Any current treatment with anticonvulsants, cortisone, tricyclic antidepressants
* Other lesions (glomus tumors, meningiomas, adenomas, vascular lesions or neuro-vascular conflicts) detected by clinical assessment
* Serious, concomitant disorder, including major depression, anxiety
* Any condition that, in the judgment of the investigator, might prevent safe participation in the study or interfere with study objectives
* Inability to comply with the protocol requirements
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Competence Center for Medical Devices GmbH
UNKNOWN
Pansatori GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PANSATORI-001
Identifier Type: -
Identifier Source: org_study_id